Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Has Average Target Price of $8.75 According to Brokerages

Prelude Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Five of seven analysts rate Prelude Therapeutics a buy, while one recommends hold and one sell; the average 12-month price target is $8.75.
  • Quarterly results missed expectations: Prelude reported a loss of $0.12 per share versus consensus expectations for $0.01 in earnings, and revenue of $5.65 million compared with estimates of $29 million.
  • Shares opened at $3.26, below their 50-day and 200-day moving averages of $3.86 and $4.10, respectively. Institutional investors own about 79.7% of the company’s shares.
  • Five stocks we like better than Prelude Therapeutics.

Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.75.

PRLD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. began coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They set an "overweight" rating and a $12.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $8.00 target price on shares of Prelude Therapeutics in a research note on Wednesday. Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, September 19th. Citigroup restated a "market outperform" rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th.

Check Out Our Latest Report on Prelude Therapeutics

Prelude Therapeutics Stock Performance

Shares of NASDAQ:PRLD opened at $3.26 on Friday. The company has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $4.10. The company has a market capitalization of $260.15 million, a PE ratio of -5.53 and a beta of 1.22. Prelude Therapeutics has a 52 week low of $1.29 and a 52 week high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.13). The company had revenue of $5.65 million for the quarter, compared to analyst estimates of $29.00 million. On average, sell-side analysts forecast that Prelude Therapeutics will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On Prelude Therapeutics

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of Prelude Therapeutics by 451.8% in the third quarter. Goldman Sachs Group Inc. now owns 666,778 shares of the company's stock valued at $2,607,000 after purchasing an additional 545,944 shares during the last quarter. Empowered Funds LLC acquired a new position in Prelude Therapeutics during the third quarter worth $235,000. Polymer Capital Management US LLC acquired a new position in Prelude Therapeutics during the third quarter worth $55,000. Squarepoint Ops LLC acquired a new position in Prelude Therapeutics during the second quarter worth $317,000. Finally, Spark Investment Management LLC bought a new position in Prelude Therapeutics in the second quarter valued at $56,000. Institutional investors own 79.72% of the company's stock.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude's pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

See Also

Analyst Recommendations for Prelude Therapeutics (NASDAQ:PRLD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prelude Therapeutics Right Now?

Before you consider Prelude Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.

While Prelude Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines